Potential Clinical Utility of a New IRMa for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism

Vincenzo Carnevale, Simona Dionisi, Italo Nofroni, Elisabetta Romagnoli, Federica Paglia, Simona De Geronimo, Jessica Pepe, Giovanni Clemente, Gianfranco Tonnarini, Salvatore Minisola

Research output: Contribution to journalArticle

Abstract

Background: A new commercially available (so-called second-generation) IRMA for parathyroid hormone (PTH) separately detects intact PTH and its N-truncated fragments; however, no studies have compared the first-and second-generation IRMAs for PTH in patients with primary hyperparathyroidism (PHPT) to assess their respective diagnostic accuracies. Methods: We concomitantly investigated 39 postmenopausal patients with PHPT and a control group of 70 healthy postmenopausal women matched for age, renal function, and vitamin D status. In all individuals, PTH was measured with a classic IRMA (PTH-S; DiaSorin Inc.), which uses antibodies directed against epitopes 1-34 and 39-84, and a new method (Scantibodies Laboratory. Inc.), which uses antibodies against epitopes 1-4 and 39-84 (PTH-W) and epitopes 7-34 and 39-84 (PTH-T). We also assayed serum PTH in 10 PHPT patients every 24 h for 5 days after successful surgery. Results: The different assays gave serum PTH values that were >2 SD higher than values for the control population in 59% (PTH-S), 77% (PTH-W), and 82% (PTH-T) of patients with PHPT. However, ROC curve analysis showed no significant differences among the three PTH assays, demonstrating overlapping diagnostic sensitivities. In PHPT patients, the correlation among the assays was highly significant (r = 0.91-0.92; P

Original languageEnglish
Pages (from-to)626-631
Number of pages6
JournalClinical Chemistry
Volume50
Issue number3
DOIs
Publication statusPublished - Mar 2004

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Potential Clinical Utility of a New IRMa for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism'. Together they form a unique fingerprint.

  • Cite this

    Carnevale, V., Dionisi, S., Nofroni, I., Romagnoli, E., Paglia, F., De Geronimo, S., Pepe, J., Clemente, G., Tonnarini, G., & Minisola, S. (2004). Potential Clinical Utility of a New IRMa for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism. Clinical Chemistry, 50(3), 626-631. https://doi.org/10.1373/clinchem.2003.026328